Correctly diagnosing hypertension in children is crucial for identifying other underlying conditions and allowing for earlier treatment and better outcomes, explained Tammy Brady, MD, PhD, medical director of the Pediatric Hypertension Program and associate professor of pediatrics at Johns Hopkins University.
Correctly diagnosing hypertension in children is crucial for identifying other underlying conditions and allowing for earlier treatment and better outcomes, explained Tammy Brady, MD, PhD, medical director of the Pediatric Hypertension Program and associate professor of pediatrics at Johns Hopkins University.
Transcript
What are the dangers of missed or incorrect diagnosis of hypertension in children?
Hypertension in childhood is often the result of another condition, frequently related to the kidney but can also be related to rheumatologic diseases, endocrine disorders, and so elevated blood pressure is often the first sort of sign that there’s something else going on. And so by missing elevated blood pressure, underdiagnosing this, you’re missing an opportunity to diagnose and identify another condition, and many of those conditions, the earlier that they’re identified and treated really can be the most impactful in terms of the outcomes.
As an example, in pediatric nephrology, say a child who has focal segmental glomerulosclerosis, he or she may feel fine and have no outward signs that anything is going on with their kidney; however, they may have an elevated blood pressure that’s identified at their primary care doctor for whatever reason, and that elevated blood pressure will prompt a work-up that will ultimately identify proteinuria and elevated creatinine, and that will allow for earlier intervention and earlier treatment, which can delay kidney disease progression and potentially even prevent end-stage renal disease from developing.
In terms of overdiagnosis, certainly with overdiagnosis comes the risk of having overutilization, overtesting, potentially inducing anxiety in the child or the family, but I actually in my experience find this to be less of a problem. Certainly this is a problem if you rely on the first blood pressure that’s obtained in a clinic setting, but the American Academy of Pediatrics has really tried to emphasize the need for repeated measurements in a clinic setting over repeated visits and additionally the use of ambulatory blood pressure monitoring prior to even giving a child a diagnosis of hypertension or even initiating a work-up. And so hopefully as these guidelines get more broadly implemented, overdiagnosis will be less of a problem.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More